Mylan N.V. (MYL) Shares Sold by Prudential Financial Inc.
Prudential Financial Inc. cut its stake in Mylan N.V. (NASDAQ:MYL) by 25.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,224,127 shares of the company’s stock after selling 416,189 shares during the period. Prudential Financial Inc. owned about 0.23% of Mylan N.V. worth $38,401,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of MYL. Pzena Investment Management LLC grew its holdings in shares of Mylan N.V. by 69.9% in the second quarter. Pzena Investment Management LLC now owns 12,339,687 shares of the company’s stock worth $479,027,000 after purchasing an additional 5,077,371 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Mylan N.V. by 12.0% in the second quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock worth $1,276,432,000 after purchasing an additional 3,531,974 shares during the last quarter. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management purchased a new stake in Mylan N.V. in the second quarter worth about $84,364,000. BlackRock Inc. lifted its stake in Mylan N.V. by 4.5% in the second quarter. BlackRock Inc. now owns 40,574,158 shares of the company’s stock worth $1,575,089,000 after acquiring an additional 1,751,515 shares during the period. Finally, Schroder Investment Management Group lifted its stake in Mylan N.V. by 161,445.9% in the second quarter. Schroder Investment Management Group now owns 1,731,772 shares of the company’s stock worth $67,124,000 after acquiring an additional 1,730,700 shares during the period. Hedge funds and other institutional investors own 73.75% of the company’s stock.
Mylan N.V. (NASDAQ MYL) opened at $38.16 on Monday. The company has a market cap of $20,470.41, a P/E ratio of 8.12, a P/E/G ratio of 2.09 and a beta of 1.38. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. Mylan N.V. has a 1 year low of $29.39 and a 1 year high of $45.87.
Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings data on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). The company had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. Mylan N.V. had a net margin of 7.28% and a return on equity of 20.63%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.38 earnings per share. research analysts anticipate that Mylan N.V. will post 4.56 earnings per share for the current fiscal year.
A number of research firms recently weighed in on MYL. Zacks Investment Research lowered shares of Mylan N.V. from a “buy” rating to a “hold” rating in a research note on Wednesday, November 8th. Royal Bank Of Canada upped their price objective on shares of Mylan N.V. from $32.00 to $37.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 7th. Cantor Fitzgerald set a $34.00 price objective on shares of Mylan N.V. and gave the stock a “hold” rating in a research note on Tuesday, October 31st. BidaskClub raised shares of Mylan N.V. from a “hold” rating to a “buy” rating in a research note on Friday, October 27th. Finally, Mizuho reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Mylan N.V. in a research note on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $41.49.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan N.V. (NASDAQ:MYL).
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.